조사회사 : BCC Research 출판년월 : 2024년01월
Next-generation Sequencing: Emerging Clinical Applications and Global Markets
차세대 시퀀싱의 임상 적용을 위한 세계 시장은 2023년부터 2028년까지 연평균 복합 성장률(CAGR) 19.3%로 성장해 2023년 219억 달러에서 2028년 529억 달러에 이를 것으로 추정됩니다.| 페이지 수 | 492 |
| 도표 수 | 293 |
| 가격 |
Report Highlights
The global market for clinical applications of next-generation sequencing is estimated to increase from $21.9 billion in 2023 to reach $52.9 billion by 2028, at a compound annual growth rate (CAGR) of 19.3% from 2023 through 2028.
Summary:
Since NGS platforms can sequence an entire genomic region or even an entire genome, a single test can examine hundreds or thousands of clinically important genetic variations. This means that one test can replace multiple conventional single-gene tests, providing an advantage in price and in the amount of precious sample needed for the test itself.
NGS is often more accurate and reliable than existing diagnostics. This can result in better clinical outcomes. For example, NGS can increase the pregnancy success rates in in vitro fertilization applications. Also, in rare genetic diseases, NGS can increase the success rates for determining a molecular diagnosis.
The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test. This strategy has been employed in reproductive health applications, for example, launching a test to initially screen for aneuploidies, and then later expanding the test to include screening for additional genetic variants.
These features of NGS platforms provide a solid basis for the use of this technology in the clinic.
Report Scope:
The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies. The markets for NGS-based diagnostics are given for the years 2020, 2021, 2022, 2023 and 2028.
This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed.
The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.
The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health, and transplant medicine.
Specific geographic markets are discussed, namely North America, Europe, Asia-Pacific, and the Rest of the World.
Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct-to-consumer testing; and noninvasive prenatal testing.
More than 100 companies in the clinical NGS industry are profiled in this report.
BCC Research also provides a summary of the recent, primary industry acquisitions and strategic alliances, including key alliance trends.
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2022 |
| Forecast period considered | 2023-2028 |
| Base year market size | $18.4 billion |
| Market size forecast | $52.9 billion |
| Growth rate | CAGR of 19.3% for the forecast period of 2023-2028 |
| Units considered | $ Millions |
| Segments covered | Disease Class, Test Complexity, Analysis Type, and Geographic Region |
| Regions covered | North America, Europe, Asia-Pacific, and Rest of the World |
| Countries covered | Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Iceland, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Spain, Switzerland, Turkey, UK, Sweden, Australia, China, India, Japan, Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand, South Korea, Argentina, Brazil, Chile, Israel, Kuwait, Russia, Saudi Arabia, South Africa, UAE |
| Key Market Drivers | Growing demand for precision medicine. Emergence of tissue-agnostic drug labels Increasing endorsement of liquid biopsy-based diagnostics from key industry stakeholders Emergence of several high market potential (“mega”) applications |
| Companies studied | AGILENT TECHNOLOGIES INC. BGI GENOMICS CO. LTD ILLUMINA INC. QIAGEN THERMO FISHER SCIENTIFIC INC. ACCURAGEN HOLDINGS ADAPTIVE BIOTECHNOLOGIES ALCEN AMBRY GENETICS AMOY DIAGNOSTICS CO. LTD. ANGLE PLC APOSTLE SCIENCES ARCEDI BIOTECH APS ARMONICA TECHNOLOGIES INC. ARUP LABORATORIES ASURAGEN INC. BAYLOR GENETICS BECTON, DICKINSON AND CO. BERRY GENOMICS BEIJING BIOCAPTIVA LTD. BIOCEPT INC. BIODESIX BIOLIDICS LTD BIOFLUIDICA BIOLOGICAL DYNAMICS BIOMODAL BIONANO GENOMICS BIO-RAD LABORATORIES INC. BIO-TECHNE C2I GENOMICS CAPIO BIOSCIENCES CAREDX INC. CARIS LIFE SCIENCE CEGAT GMBH CELL MICROSYSTEMS CENTRILLION GENOMICS TECHNOLOGIES CLARET BIOSCIENCE CLEAR NOTE HEALTH CLINICAL GENOMICS TECHNOLOGIES CYCLOMICS CYGNUS BIOSCIENCES CO. LTD. DANAHER DANTE LABS DATAR CANCER GENETICS LTD. DELFI DIAGNOSTICS DIACARTA DIAGNOLOGIX LLC DIAGNOMICS INC. DIAMIR BIO DNALYTICS DNANEXUS INC. EARLYDIAGNOSTICS EONE-DIAGNOMICS GENOME CENTER CO. LTD. EPIC SCIENCES EPIGENOMICS AG EUROFINS GENOMICS EVERLY HEALTH INC. EXACT SCIENCES CORP. EXOPERT EXOSOMICS INC. EZLIFE BIO FABRIC GENOMICS INC. F. HOFFMANN-LA ROCHE LTD FLUXION BIOSCIENCES INC. FREENOME HOLDINGS INC. FULGENT GENETICS FULL GENOMES CORP. GENE BY GENE LTD. GENEDX LLC GENESEQ BIOSCIENCES GENOMONCOLOGY LLC GENOSABER GRAIL INC. GUARDANT HEALTH HELIO GENOMICS HELIX INC. HTG MOLECULAR DIAGNOSTICS INC. IMAGIA CANEXIA HEALTH INCELLDX INC. INEX INNOVATE PRIVATE LTD INOVIQ INTERPACE BIOSCIENCES INC. INVITAE CORP. INVIVOSCRIBE INC. JABREHOO MED TECH CO. LTD. JBS SCIENCE JUMPCODE GENOMICS INC. KONINKLIJKE PHILIPS N.V. LABGENOMICS CO. LTD. LABORATORY CORPORATION OF AMERICA HOLDINGS LIQUID BIOPSY LABS LUCENCE HEALTH INC. LUNGLIFE AI INC. MACROGEN INC. MAPMYGENOME MDXHEALTH INC. MEDGENOME MEDICOVER GENETICS MENARINI SILICON BIOSYSTEMS SPA MERCK KGAA MICAREO RARE CELL DIAGNOSTICS MICRONOMA INC. MIR SCIENTIFIC MUTANTDX MYRIAD GENETICS INC. NANOSTRING TECHNOLOGIES INC. NATERA INC. NEBULA GENOMICS NEOGENOMICS LABORATORIES NEW ENGLAND BIOLABS NEW HORIZON HEALTH LTD. NOVIGENIX SA NOVOGENE CO. LTD. NRICHDX INC. NUPROBE INC. NX PRENATAL INC. ONCIMMUNE HOLDINGS PLC ONCOCYTE CORP. PANGAEA ONCOLOGY ONCODNA OPKO HEALTH ORCHID OXFORD NANOPORE TECHNOLOGIES LTD. PACIFIC BIOSCIENCES OF CALIFORNIA INC. PERSONAL GENOME DIAGNOSTICS INC. PERSONALIS INC. PHASE SCIENTIFIC PIERIANDX PREDICINE PRENETICS GROUP QCDX LLC QUANTAPORE QUANTGENE INC. QUANTUMDX QUEST DIAGNOSTICS RARECELLS INC. RAVGEN REAL TIME GENOMICS RESOLUTION BIOSCIENCE INC. SAGA DIAGNOSTICS AB SANO GENETICS SCREENCELL SEEKIN INC. SEQUENCING.COM SEVEN BRIDGES GENOMICS INC. SINGLE TECHNOLOGIES SMARTCATCH STAGEZERO LIFE SCIENCES. LTD. STRAND STRATA ONCOLOGY SYAPSE INC. SYSMEX INOSTICS GMBH TAKARA BIO INC. TELEXOS GMBH TWINSTRAND BIOSCIENCES INC. TWIST BIOSCIENCE UNCHAINED LABS UNIVERSAL DX VELA DIAGNOSTICS VERACYTE VOLITIONRX VORTEX BIOSCIENCES YOURGENE HEALTH YIKON GENOMICS CO. LTD. |
Report Includes:
- 41 data tables and 237 additional tables
- An overview of the global market for emerging clinical applications of next-generation sequencing
- Analysis of global market trends, featuring historical revenue data for 2020 to 2022, estimates for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by disease indication, test complexity, test purpose, application and geographic region
- Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenarios and use of NGS-based diagnostics and technologies
- Coverage of genome mapping programs, technological advances and innovations in NGS platforms, and the Ion Torrent Genexus System from Thermo Fisher Scientific and the Magnis NGS Prep System lfrom Agilent Technologies Inc
- Description of NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT), and a discussion of their advantages
- Market share analysis of the key companies and a look at their proprietary technologies, strategic alliances and other key market strategies, plus a patent analysis
- Profiles of the leading players, including Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN, Agilent Technologies Inc., and BGI Genomics
Table of Contents
